

The Effect of Leptin Receptor Gene Polymorphisms (R223Q and P1019P) in Susceptibility to Polycystic Ovarian Syndrome in Kurdish Women

Rozita Naseri, Ph.D.¹, Elahe Barzingerosi, Ph.D.¹, Maryam Sohrabi, M.D.², Yosra Alimoradi, Ph.D.¹,
Mostafa Cheraghian Fard, M.D.³, Cyrus Jalili, Ph.D.^{4*}

1. Internal Medicine Department, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
2. Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
3. Department of Anatomical Sciences, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran
4. Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

Abstract

Background: Polycystic ovary syndrome (PCOS) is the known endocrinopathy disorder in the reproductive phase of women's life. More than half of the women with PCOS suffer from obesity which impacts the ovarian functions by leptin levels. Here the R223Q and P1019P polymorphisms of leptin receptor (*LEPR*) gene were examined in PCOS patients of Kurdish women from west of Iran.

Materials and Methods: In this case-control study, one hundred women with PCOS and 100 healthy women bearing similar age range were selected based on Rotterdam diagnostic criteria. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to genotype polymorphisms *LEPR* (R223Q and P1019P), by respectively the BsaWI and NcoI restriction enzymes. Pearson's chi-square (χ^2) test was used to analyze the variation in genetic distributions and unconditional logistic regression model was used to calculate the odds ratio (OR; 95% CI).

Results: Genotype frequencies of the R223Q and P1019P polymorphisms showed significant difference between the patients with PCOS compared to the controls. G allele (R223Q) reduced the risk of PCOS about 0.49-fold ($P < 0.001$). While, T allele (P1019P) increased the risk of PCOS 2.69-fold ($P < 0.001$).

Conclusion: It can be concluded that the R223Q and P1019P polymorphisms showed a significant association with PCOS susceptibility risk. It seems that G allele (R223Q) with reducing OR had a protective effect on this syndrome, while T allele (P1019P) with increasing OR was a risk factor for PCOS.

Keywords: Kurdish Population, *LEPR*, Leptin Receptor, Obesity, Polycystic Ovary Syndrome

Citation: Naseri R, Barzingerosi E, Sohrabi M, Alimoradi Y, Cheraghian Fard M, Jalili C. The effect of leptin receptor gene polymorphisms (R223Q and P1019P) in susceptibility to polycystic ovarian syndrome in Kurdish women. *Int J Fertil Steril*. 2021; 15 (2): 123-127. doi: 10.22074/IJFS.2021.6197.

This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).

Introduction

Polycystic ovary syndrome (PCOS), as a heterogeneous disorder, is yet unexplained and its etiology has uncovered. It is the most common endocrinopathy disorder in the reproductive phase of women life (1) that affects nearly 6-8% of women in this phase (2). The phenotype of PCOS is described by chronic oligoanovulation, hyperandrogenism and polycystic ovarian morphology (3). This complex multi-system syndrome is also associated with hirsutism, insulin resistance and obesity (4).

Besides, as a major cause of infertility, PCOS is often associated with metabolic syndrome characteristics, such as insulin resistance, chronic proinflammatory state, dyslipidemia, increased central or visceral adiposity, etc. The

large overlap between features of PCOS and metabolic disorder suggests that dysregulation in the function of adipose tissue contributes to some metabolic dysregulation of PCOS patients, similar to what happens in metabolic disorders (5). Obesity, leading to fat content accumulation in the body especially in adipose tissue, can be considered as a metabolic illness (6, 7).

Adipose tissue by secreting the numerous hormones plays an important role in the metabolism of lipid and carbohydrate, regulation of energy homeostasis, as well as sensitivity to insulin. Cytokines or cytokine-like molecules, including leptin, are the major proportion of these secreted factors which play critical role in immunomodulatory effects and inflammatory responses (5, 8).

Received: 16 December 2019, Accepted: 22 June 2020

*Corresponding Address: P.O.Box: 1565, Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
Email: cjalili@yahoo.com



Royan Institute
International Journal of Fertility and Sterility
Vol 15, No 2, April-June 2021, Pages: 123-127

Leptin, which is dysregulated in obesity, is a polypeptide hormone with 16 kDa weight, produced mainly by white adipose tissue and secreted by lipocytes: leptin can affect the immune processes, hematopoiesis, angiogenesis and reproduction (9). In addition, leptin is involved in the metabolism and function of certain tissues (10).

A significant percentage of patients with PCOS have both reproductive dysfunction and obesity (11). Obesity which modify insulin sensitivity and dynamics of gonadotropin is also associated with ovulation disorders (12). It has been suggested that obesity impacts ovarian functions in patient with PCOS, in part, due to the enhanced intra-follicular levels of leptin and it may cause comparative resistance to gonadotropins (13). There are several polymorphic genes in leptin regulation. Single nucleotide polymorphism (SNP) in the leptin and leptin receptor (LEPR) have been studied as factors that may be associated with PCOS and obesity, which is reported in more than half of the women with PCOS (14-16).

So, the aim of present study was to investigate association of PCOS with two important SNPs in the *LEPR* gene (R223Q and P1019P) within the Kurdish women population from west of Iran.

Materials and Methods

Subjects

In this case-control study, overall 200 Kurdish women (Kermanshah province, west region of Iran) including 100 women with PCOS and 100 healthy women were examined. Selection of the patients and controls were verified by a gynecologist in accordance to the revision of Rotterdam diagnostic criteria (15). Accordingly, to consider as PCOS patient, each case had to have, at least, two of the following three criteria. Participants were informed about the purpose of project and signed the informed consent (according to the Helsinki II declaration).

This project was also approved by Ethical Committee of Kermanshah University of Medical Sciences (IR.KUMS.REC.1397.249).

DNA extraction

DNA extraction from samples (1 ml whole blood) was carried out according to the Moradi et al. (17) method. Integrity of the extracted DNA were distinguished by agarose gel electrophoresis and NanoDrop spectrophotometer (Thermo Fisher, USA) was used to determine concentration of DNA.

Genotyping

Analysis of *LEPR* gene polymorphisms (R223Q and P1019P) were done using polymerase chain reaction (PCR) amplification, followed by restriction fragment length polymorphism (RFLP) techniques. PCR assay was performed in a total volume of 25 µl. It was including 2.5 µl of 10X PCR buffer, 20 pmol of each primer (Table 1), 1.5 mM MgCl₂, 0.2 mM dNTPs, 1 Unit Taq

DNA polymerase (SinaClonBioScience Co., Iran) and 100 ng isolated DNA as PCR template. The defined condition for thermal cycler included an initial denaturation at 95°C for 2 minutes, 30 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C (*LEPR* R223Q)/53°C (*LEPR* P1019P) for 30 seconds, extension at 72°C for 40 seconds, and then a final extension at 72°C for 5 minutes. After amplification, about 10 µl PCR products were subjected to overnight digestion with 1-2 units of restriction enzymes. Products of the digestion were visualized by 2% agarose gel stained with GelRED under ultraviolet light. In the case of R223Q genotyping, BsaWI (Thermo Fisher, USA) at 60°C produced a 279 bp band (AA genotype), 279 bp, 193 bp, and 86 bp bands (AG genotype), or 193 bp and 86 bp bands (GG genotype, Fig.1A). For P1019P genotyping, NcoI (Thermo Fisher, USA) at 37°C produced a 253 bp band (CC genotype), 253 bp and 223 bp bands (CT genotype) or 223 bp band (TT genotype, Fig.1B).

Table 1: The primers used for detection of R223Q and P1019P polymorphisms

NCBI rs	SNP	Primer sequences (5'-3')	Method of detection
rs1137101	R223Q	F: ttgtgaatgtcttctgacct R: agaagccactcttaataccc	RFLP-PCR
rs1805096	P1019P	F: cagatcttgaaaagggttct R: tcccatgagctattagagaagaatcctcca	RFLP-PCR

SNP: Single nucleotide polymorphism, RFLP: Restriction fragment length polymorphism, and PCR: Polymerase chain reaction.




Fig.1: Agarose gel electrophoresis (2%) for PCR product of gene polymorphisms. **A.** PCR product of *LEPR* gene polymorphism (R223Q) on 2% agarose gel. Lines (1) 50 bp DNA ladder, (2) a homozygous individual (AA) with 279 bp band, (3) a heterozygous individual (AG) with 279 bp, 193 bp and 86 bp bands and (4) homozygous individuals (GG) with 193 bp and 86 bp bands. **B.** PCR product of *LEPR* gene polymorphism (P1019P) on 2% agarose gel. Lines (1) 50 bp DNA ladder, (2) a homozygous individual (CC) with 253 bp band, (3) a heterozygous individual (CT) with 253 bp and 223 bp bands and (4) homozygous individuals (TT) with 223 bp band. PCR; Polymerase chain reaction.

Statistical analysis

Statistical analyses were done by SPSS software (V.16). Pearson's chi-square (χ^2) test was utilized to analyze the variation in genetic distributions and unconditional logistic regression model for calculating the odds ratio (OR; 95% CI) and interaction between R223Q and P1029P polymorphisms were used. P<0.05 was considered statistically significant.

Results

In this study, we examined 100 patients with PCOS and 100 normal controls. Frequency of the patients with PCOS were in Hardy Weinberg equilibrium (P=0.15 for R223Q, P=0.49 for P1019P). There was no significant difference in terms of ages between PCOS patients and controls (the mean age was 28.34 ± 4.58 years for patients and 27.09 ± 5.19 years for controls, P=0.07). Although in terms of body mass index (BMI), it was significantly different (29.14 ± 2.68 for patients and 23.05 ± 2.48 for controls, P<0.001).

The results of this study indicated that genotypic frequency of the R223Q polymorphism was significantly different in the patients with PCOS compared to the controls (Table 2). For R223Q polymorphism, in comparison with controls, AG genotype might associate with 0.41-fold decreased risk of PCOS (P=0.01). G allele also reduced risk of PCOS approximately 0.49-fold (P<0.001). Genotype frequency of P1019P polymorphism was significantly different between the patients with PCOS and the controls. For P1019P polymorphism, in comparison with the controls, TC genotype might associate with 2.43-fold increased risk of PCOS (P=0.007) T allele also increased the risk of PCOS approximately 2.69-fold (P<0.001, Table 3). Study the interaction of D151A and R453Q genotypes showed 0.51-fold decrease in the risk of PCOS (P=0.02) for the carriers of D151A (AA genotype) and R453Q (AG or AA genotypes), but there was no significant correlation between other combinations of the D151A and R453Q genotypes and risk of PCOS (Table 4).

In order to investigate the association of the gene polymorphisms with BMI, and age, the total participants (patients and healthy controls) were divided into two groups: in terms of BMI (≤25 and >25) and age (≤30 and >30 years old). Results showed that the frequency of genotypes (R223Q/P1019P) had no significant difference in the subgroups divided by age and BMI (Table 5).

Table 2: Frequency of R223Q genotypes and alleles

Frequency	Controls n (%)	Patients n (%)	Odds ratio (95% CI)	P value
Genotypes				
AA	17 (17)	37 (37)	1	
AG	59 (59)	53 (53)	0.41 (0.21-0.81)	0.01
GG	24 (24)	10 (10)	0.19 (0.075-0.48)	<0.001
AG+GG	83 (83)	63 (63)	0.35 (0.18-0.67)	0.001
Alleles				
A	93	127	1	
G	107	73	0.49 (0.33-0.74)	<0.001

Overall $\chi^2= 13.494$. CI; Confidence interval.

Table 3: Frequency of P1019P genotypes and alleles

Genotypes	Controls n (%)	Patients n (%)	Odds ratio (95% CI)	P value
P1019P				
CC	80 (80)	59 (59)	1	
TC	19 (19)	34 (34)	2.43 (1.29-4.66)	0.007
TT	1 (1)	7 (7)	9.49 (1.14-79.24)	0.03
TC+TT	20 (20)	41 (41)	2.78 (1.48-5.23)	0.001
Alleles				
C	179	152	1	
T	21	48	2.69 (1.54-4.7)	<0.001

Overall $\chi^2= 13.494$. CI; Confidence interval.

Table 4: Interaction between genotypes of R223Q and P1019P on confidence interval

R223Q	P1019P	Odds ratio (95% CI)	P value
AA	CC	1.63 (0.92-2.85)	0.089
AG+GG	CC	2.14 (0.77-5.94)	0.14
AA	TC+TT	0.51 (0.28-0.9)	0.02
AG+GG	TC+TT	0.73 (0.24-2.19)	0.58

CI; Confidence interval.

Table 5: Association of age and BMI with the genotypes of R223Q and P1019P polymorphisms

SNP	Genotype	BMI		Odds ratio (95% CI)	P value	Age (Y)		Odds ratio (95% CI)	P value
		≤25	>25			≤30	>30		
R223Q	AA	50	62	1		41	13	1	
	AG	30	24	0.64 (0.33-1.24)	0.18	83	29	1.1 (0.52-2.34)	0.8
	GG	21	13	0.49 (0.28-1.09)	0.08	22	12	1.72 (0.67-4.4)	0.25
P1019P	CC	54	75	1		92	49	1	
	CT	25	38	1.09 (0.59-2.02)	0.77	31	20	1.2 (0.62-2.34)	0.56
	TT	2	6	2.16 (0.42-11.11)	0.36	5	3	1.12 (0.25-4.9)	0.87

SNP; Single-nucleotide polymorphism, BMI; Body mass index, and CI; Confidence interval.

Discussion

According to our best knowledge, as a novel study in an Iranian population, we evaluated the association between PCOS and two *LEPR* gene polymorphisms (R223Q and P1019P). Here we showed that both variants of *LEPR* (R223Q and P1019P) are related to PCOS susceptibility. Additionally, it seems that G allele (R223Q) has a protective effect on this disease and reduces the corresponding risk of PCOS, while T allele (P1019P) increases the corresponding risk. In addition, based on our results, it seems there is no correlation between these polymorphisms with BMI and age.

Increasing evidences indicated that there was an overlap among the obesity and other metabolic disorders, such as metabolic syndrome, diabetes mellitus and PCOS (18). Villa and Pratley (5) by comparing gene expression profiles in adipose tissue of patients with PCOS and normal control group, showed different dysregulated genes in several ontological classes. They found dysregulated genes were involved in immune function, cell growth, insulin signaling, lipid metabolism and metabolic syndromes. On the other hand, researchers believe that the strong association between obesity and PCOS can refer to the relation between PCOS and obesity-susceptibility variants (19).

Bioactive cytokines and adipokines, including the resistin, adiponectin and leptin, are released from fat tissue (20). It was suggested that there is an association between leptin dysregulation and the onset of obesity as well as the obesity-related pathologies such as PCOS (21, 22). Leptin has important role in the physiology of reproductive system. It has intricate interactions at the hypothalamic-pituitary-gonadal axis such as inhibitory actions at the gonads and stimulatory effects at the pituitary and hypothalamus (23). In total, it is suggested that leptin and its receptor (*LEPR*) may contribute to the insulin metabolism, energy homeostasis and ovarian androgen synthesis related to PCOS (24).

SNPs of the *LEPR* gene have been investigated in various local populations and different diseases like breast cancer, non-small-cell lung cancer, oral squamous cell carcinoma, diabetic macroangiopathy and essential hypertension (25-28). However, few studies have addressed the relationship of *LEPR* variants and PCOS. Two known polymorphisms of *LEPR* are R223Q and P1019P. Although the biological functions of these two polymorphisms are not fully understood, it has been reported that R223Q and P1019P are respectively found in the extracellular and intracellular regions of the receptor and separately involved in cytokine motifs and ligand binding. Similar to our study, a case-control study in a Korean population reported significant association between the variants of *LEPR* (R223Q and P1019P) and risk of PCOS (29). While a case-control study in Finland reported no association between the *LEPR* variants and PCOS, they declared variations in the *LEPR* locus has affected the insulin regulation, as a hypothesis (16). Tu et al. (30) suggested that there is no

significant association between *LEPR* R223Q and PCOS in a Chinese population; however, our data demonstrated a protective effect of G allele (R223Q) against PCOS. In addition, a meta-analysis study in Chinese population showed that two variants of *LEPR* (R223Q and P1019P) are related to obesity (31).

Conclusion

This is the first report on the relationship of *LEPR* gene variants and PCOS in a population of women from Iran. Here, we showed that R223Q and P1019P of the *LEPR* were risk factors for PCOS susceptibility. This may be useful in biomarker detection and future approaches of PCOS gene therapy. However, it needs to be approved in larger population with different races.

Acknowledgements

We are thankful for the Research Council of Kermanshah University of Medical Sciences that supported this project (grant number 97336). The authors declare no conflict of interest.

Authors' Contributions

C.J.; Designed the proposal of study and contributed to manuscript editing. R.N.; Contributed to conception and design. E.B., Y.A.; Contributed to the sample collection and interpretation of data. M.S.; Contributed to the data analysis, experimental works and drafted the manuscript. M.C.F.; Contributed to the sample collection and some of the experimental works. All authors read and approved the final manuscript.

References

1. Hartmann G, McEwen B. Insulin resistance and polycystic ovary syndrome (pcos): part 2. Diet and nutritional medicine. *J AUST TRADIT-MED SO.* 2019; 25(1): 18-22.
2. Teasdale A, Gale K, Holloway D. Menstrual and hormonal dysfunction. *Nursing management of women's health.* Switzerland: Springer Nature; 2019; 7-47.
3. Lauritsen MP, Svendsen PF, Andersen AN. Diagnostic criteria for polycystic ovary syndrome. *Ugeskr Laeger.* 2019; 181(15): V12180845.
4. Hague WM, Adams J, Reeders ST, Peto TEA, Jacobs HS. Familial polycystic ovaries: a genetic disease? *Clin Endocrinol.* 1988; 29(6): 593-605.
5. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. *Curr Diab Rep.* 2011;11(3): 179-184.
6. Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: a comprehensive review. *C R Biol.* 2017; 340(2): 87-108.
7. Yang Q, Xiao T, Guo J, Su Z. Complex relationship between obesity and the fat mass and obesity locus. *Int J Biol Sci.* 2017; 13(5): 615-629.
8. Lu H, Sun J, No N, Xu Y, Xie D, Sun L, et al. Association between the leptin receptor gene polymorphism and lipoprotein profile in Chinese type 2 diabetes. *Diabetes Metab Syndr.* 2007; 1(4): 259-265.
9. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, Chouchane L. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. *BMC Cancer.* 2006; 6: 38.
10. Houseknecht K, Portocarrero C. Leptin and its receptors: regulators of whole-body energy homeostasis. *Domest Anim Endocrinol.* 1998; 15(6): 457-475.
11. Zhai J, Liu Cx, Tian Zr, Jiang Qh, Sun Yp. Effects of metformin on

- the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. *Biol Reprod.* 2012; 87(2): 29, 1-5.
12. Maliqueo M, Perez-Bravo F, Calvillan M, Piwonka V, Castillo T, Sir-Petermann T. Relationship between leptin and insulin sensitivity in patients with polycystic ovary syndrome. *Medicina Clinica.* 1999; 113(14): 526-530.
 13. Pinilla L, Seoane LM, González-Matías LC, Carro E, Aguilar E, Casanueva FF, et al. Regulation of serum leptin levels by gonadal function in rats. *Eur J Endocrinol.* 1999; 140(5): 468-473.
 14. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. *Am J Epidemiol.* 2005; 162(2): 101-114.
 15. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril.* 2004; 81(1): 19-25.
 16. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen SL, Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. *Mol Hum Reprod.* 2000; 6(10): 873-876.
 17. Moradi MT, Yari K, Khodarahmi R. A novel, efficient, fast and inexpensive DNA extraction protocol from whole blood applicable for studying drug-DNA interaction. *J Rep Pharm Sci.* 2014; 3(1): 80-84.
 18. Fazleen NE, Whittaker M, Mamun A. Risk of metabolic syndrome in adolescents with polycystic ovarian syndrome: A systematic review and meta-analysis. *Diabetes Metab Syndr.* 2018; 12(6): 1083-1090.
 19. Liu AL, Xie HJ, Xie HY, Liu J, Yin J, Hu JS, et al. Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. *BMC Med Genet.* 2017; 18(1): 89.
 20. Obirikorang C, Owiredu WKBA, Adu-Afram S, Acheampong E, Adu E, Antwi-Boasiakoh EK, et al. Assessing the variability and predictability of adipokines (adiponectin, leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic ovary syndrome. *BMC Res Notes.* 2019; 12(1): 513.
 21. Lecke SB, Morsch DM, Spritzer PM. Association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. *Genet Mol Res.* 2013; 12(4): 4292-4296.
 22. Lecke SB, Mattei F, Morsch DM, Spritzer PM. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. *Fertil Steril.* 2011; 95(6): 2044-2049.
 23. Pérez-Pérez A, Sánchez-Jiménez F, Maymó J, Dueñas JL, Varone C, Sánchez-Margalet V. Role of leptin in female reproduction. *Clin Chem Lab Med.* 2015; 53(1): 15-28.
 24. Chapman IM, Wittert GA, Norman RJ. Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. *Clin Endocrinol.* 1997; 46(2): 175-181.
 25. Gan RT, Yang SS. The 223A> G polymorphism of the leptin receptor gene is associated with macroangiopathy in type 2 diabetes mellitus. *Mol Biol Rep.* 2011;39(4):4759-4764.
 26. Li Y, Geng J, Wang Y, Lu Q, Du Y, Wang W, et al. The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients. *J Cancer Res Clin Oncol.* 2012;138(2):311-316.
 27. Okobia MN, Bunker CH, Garte SJ, Zmuda JM, Ezeome ER, Anyanwu SN, et al. Leptin receptor Gln223Arg polymorphism and breast cancer risk in Nigerian women: a case control study. *BMC Cancer.* 2008; 8(1): 338.
 28. Yapijakis C, Kechagiadakis M, Nkenke E, Serefoglou Z, Avgoustidis D, Vylliotis A, et al. Association of leptin -2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer. *J Cancer Res Clin Oncol.* 2009; 135(4): 603-612.
 29. Li L, Lee KJ, Choi BC, Baek KH. Relationship between leptin receptor and polycystic ovary syndrome. *Gene.* 2013; 527(1): 71-74.
 30. Tu X, Yu C, Gao M, Zhang Y, Zhang Z, He Y, et al. LEPR gene polymorphism and plasma soluble leptin receptor levels are associated with polycystic ovary syndrome in Han Chinese women. *Per Med.* 2017; 14(4): 299-307.
 31. Yang GP, Peng SH, Zuo SY, Wang YR, Peng XN, Zeng XM. Meta-analysis on the relationship between leptin receptor Gln223Arg and Pro1019Pro gene polymorphism and obesity in the Chinese population. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2011; 32(10): 1037-1042.